Curium Announces Acquisition of Lantheus for Up to $114.50 Per Share
Curium has agreed to acquire all outstanding shares of radiopharmaceutical company Lantheus Holdings (LNTH) in a cash deal valued at up to $114.50 per share. The transaction includes an initial payment of $102.50 per share, with additional contingent value rights (CVRs) that could add up to $12 more per share based on future performance or other conditions. The acquisition is expected to strengthen Curium's position in the radiopharmaceutical market by combining its distribution network and services with Lantheus' product portfolio. The deal highlights growing consolidation trends within the healthcare sector, particularly among companies involved in diagnostic imaging and nuclear medicine. From a financial perspective, this transaction could have significant implications for both firms’ stock valuations and operational synergies.
Topics: acquisition CVRs radiopharmaceuticals